Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474001 | 0.91 | IMPDH2 (0.51) | IMPDH2IMPDH1 | |
| SCHEMBL1473012 | 0.90 | IMPDH2 (0.50) | IMPDH2IMPDH1 | |
| SCHEMBL1472951 | 0.89 | IMPDH2 (0.49) | IMPDH2IMPDH1 | |
| SCHEMBL6182923 | 0.87 | IMPDH2 (0.51) | IMPDH2IMPDH1 | |
| SCHEMBL1472717 | 0.86 | IMPDH2 (0.50) | IMPDH2IMPDH1 | |
| SCHEMBL1474110 | 0.86 | IMPDH2 (0.42) | IMPDH2IMPDH1 | |
| SCHEMBL1473433 | 0.85 | IMPDH2 (0.49) | IMPDH2IMPDH1 | |
| SCHEMBL1472763 | 0.85 | IMPDH2 (0.49) | IMPDH2IMPDH1 | |
| SCHEMBL1473137 | 0.84 | IMPDH2 (0.50) | IMPDH2IMPDH1 | |
| SCHEMBL1472846 | 0.83 | IMPDH2 (0.49) | IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6399773-B1 | AUTOIMMUNE DISEASE; TRANSPLANTING ORGANS | BRISTOL-MYERS SQUIBB CO. | 2002-06-04 | — | — | US | claimed |
| EP-2803357-B1 | Angiogenesis inhibitors | UNIV JOHNS HOPKINS (US) | 2020-11-18 | — | — | EP | disclosed |
| US-9642865-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-05-09 | — | — | US | disclosed |
| US-8980930-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150056267-A1 | ANGIOGENESIS INHIBITORS | UNIV JOHNS HOPKINS (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2803357-A2 | Angiogenesis inhibitors | THE JOHNS-HOPKINS UNIVERSITY (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-20080193499-A1 | Angiogenesis Inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1786415-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-05-23 | — | — | EP | disclosed |
| EP-1765336-A2 | ANGIOGENESIS INHIBITORS | THE JOHNS-HOPKINS UNIVERSITY (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | UNIVERSITY OF QUEENSLAND (AU) | 2006-05-18 | — | — | US | disclosed |
| WO-2006017896-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006004795-A2 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-01-12 | — | — | WO | disclosed |
| US-6399773-B1 | AUTOIMMUNE DISEASE; TRANSPLANTING ORGANS | BRISTOL-MYERS SQUIBB CO. | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056267-A1 | ANGIOGENESIS INHIBITORS | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885IMPDH1 2706/4885 |
| US-20080193499-A1 | Angiogenesis Inhibitors | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885IMPDH1 2706/4885 |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885IMPDH1 2706/4885 |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | IMPDH1, IMPDH2, HADHB | IMPDH2 2/4885IMPDH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.